News
VRCA
5.08
-5.22%
-0.28
Weekly Report: what happened at VRCA last week (0803-0807)?
Weekly Report · 1h ago
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)
TipRanks · 2d ago
Verrica: Buy Rating Reiterated on YCANTH Momentum, Pivotal Wart Program Progress, and Strengthened Balance Sheet; $12 Price Target Maintained
TipRanks · 2d ago
Stacy Ku Reiterates Buy on Verrica as Ycanth’s Strong Uptake and Wart Expansion Opportunity Support Long-Term Growth
TipRanks · 3d ago
Verrica Pharmaceuticals Non-GAAP EPS of -$0.48 misses by $0.01, revenue of $5.9M beats by $0.16M
Seeking Alpha · 3d ago
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
Dow Jones · 3d ago
Weekly Report: what happened at VRCA last week (0727-0731)?
Weekly Report · 08/03 09:21
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/28 21:06
Weekly Report: what happened at VRCA last week (0720-0724)?
Weekly Report · 07/27 09:22
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Benzinga · 07/21 12:07
Weekly Report: what happened at VRCA last week (0713-0717)?
Weekly Report · 07/20 09:21
Weekly Report: what happened at VRCA last week (0706-0710)?
Weekly Report · 07/13 09:22
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/08 12:05
Weekly Report: what happened at VRCA last week (0629-0703)?
Weekly Report · 07/06 09:23
Weekly Report: what happened at VRCA last week (0622-0626)?
Weekly Report · 06/29 09:21
Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts
NASDAQ · 06/22 16:45
H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)
TipRanks · 06/22 14:15
Weekly Report: what happened at VRCA last week (0615-0619)?
Weekly Report · 06/22 09:24
Weekly Report: what happened at VRCA last week (0608-0612)?
Weekly Report · 06/15 09:24
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV
TipRanks · 06/10 16:33
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).